Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal infliximab measurement in adults with ulcerative colitis or Crohn's colitis starting infliximab
NL-OMON37225Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in autoimmune colitis and Crohn's disease, sponsored by Amsterdam University Medical Center. Primary endpoint: Infliximab level in feces. Started Dec 2012; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON37225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37225.